Pharmaceuticals News and Research

RSS

Gedeon Richter implements MediaSoft's innovative CRM solutions to improve customer-oriented services

As a specialty pharmaceutical company, Gedeon Richter remains focused on innovating and searching for advanced multichannel approaches through CRM.

13 Oct 2014

Pharmaceutical industry withdraws from the antibiotic space

The Centers for Disease Control and Prevention has said that at least 2 million Americans are sickened by antibiotic resistant infections each year and survive.

13 Oct 2014

OBN, ABPI sign MoU to build a better public profile

13 October 2014, London and Oxford: The ABPI, which represents large, medium and small innovative research-based biopharmaceutical companies in the UK and OBN, the membership organisation that brings together the UK's emerging life sciences companies, corporate partners and investors are delighted to announce their commitment to working together under a Memorandum of Understanding (MoU).

13 Oct 2014

Drugmakers sue to stop expansion of drug discount program

The trade group for pharmaceutical companies, PhRMA, has filed another lawsuit to try to block a government rule meant to widen the number of products included in a federal drug discount program for so-called safety net hospitals and clinics.

13 Oct 2014

Maker of experimental Ebola drug scales up

The manufacturer of the experimental Ebola drug ZMapp says it has put other business on hold since August to boost production of the medication. Meanwhile, news outlets look at the government's authority to screen airline travelers, the House action to release additional funding for disease-fighting efforts and the Dallas hospital's defense of its treatment of the West African man who died of the disease this week.

12 Oct 2014

Preoperative IV ibuprofen improves quality of recovery after laparoscopic cholecystectomy surgery

Cumberland Pharmaceuticals Inc. today announced that preoperative intravenous ibuprofen improved overall quality of recovery in patients undergoing laparoscopic cholecystectomy surgery. These results will be presented at the American Anesthesiology 2014 Annual Meeting in New Orleans, Louisiana.

12 Oct 2014

Isis Pharmaceuticals provides update on Phase 2 clinical studies of ISIS-SMN Rx in children with SMA

Isis Pharmaceuticals, Inc. today provided an update on its ongoing open-label Phase 2 clinical studies of ISIS-SMN Rx in infants and children with spinal muscular atrophy at the 19th International World Muscle Society (WMS) Congress in Berlin, Germany.

10 Oct 2014

European experts publish common vision of priorities for marine research

Some 340 European scientists, policy-makers and other experts representing 143 organizations from 31 countries spoke with one voice today, publishing a common vision of today's most pressing marine-related health and economic threats and opportunities.

9 Oct 2014

GE Healthcare-Glaxo Smith Kline deal to create force in cancer testing

A recently announced deal between GE Healthcare-subsidiary Clarient and Glaxo Smith Kline will create a force in cancer testing, according to Kalorama Information. The healthcare market research publisher tracks companion products, and says that the two entities will form a multi-purpose, data analytics- and companion diagnostics-driven network of laboratories. Kalorama Information recently released a market study, Companion Diagnostics Market, for companion diagnostics such as the drug-test combinations envisioned in this deal.

9 Oct 2014

VAL-083 drug compound shows promise against non-small cell lung cancer

DelMar Pharmaceuticals, Inc., a clinical-stage oncology company, today announced the presentation of promising new data supporting the activity of its lead drug compound, VAL-083, in the treatment of non-small cell lung cancer (NSCLC) at the AACR's New Horizons in Cancer Research: Harnessing Breakthroughs – Targeting Cures. The conference takes place October 9th to 12th in Pudong, Shanghai.

9 Oct 2014

HemoShear completes first-phase development of novel cancer drug discovery platform

HemoShear today announced that it has completed the first phase of development of a novel cancer drug discovery platform that replicates human tumor biology and responds to clinically-relevant drug concentrations.

9 Oct 2014

Isis Pharmaceuticals secures $18 million from GSK to advance ISIS-TTR Rx Phase 2/3 study

Isis Pharmaceuticals, Inc. announced today that it has earned an $18 million milestone payment from GlaxoSmithKline related to the advancement of the Phase 2/3 study of ISIS-TTRRx in patients with familial amyloid polyneuropathy (FAP).

9 Oct 2014

CytRx begins Phase 1b trial of aldoxorubicin plus gemcitabine in patients with metastatic solid tumors

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced the initiation of enrollment in an open-label Phase 1b clinical trial designed to investigate the preliminary safety and activity of aldoxorubicin plus gemcitabine in subjects with metastatic solid tumors.

9 Oct 2014

Endo International enters into definitive agreement to acquire Auxilium Pharmaceuticals

Endo International plc and Auxilium Pharmaceuticals, Inc. today announced that they have entered into a definitive agreement under which Endo will acquire all of the outstanding shares of common stock of Auxilium for a per share consideration of $33.25 in a cash and stock transaction.

9 Oct 2014

Impax executes definitive agreement to acquire Tower Holdings, Lineage Therapeutics

Impax Laboratories, Inc. today announced the execution of a definitive agreement under which Impax will acquire Tower Holdings, Inc., including operating subsidiaries CorePharma LLC and Amedra Pharmaceuticals LLC, and Lineage Therapeutics Inc. (together, the "Companies") for $700 million in cash, subject to certain customary purchase price adjustments.

9 Oct 2014

EPFL scientists discover two molecules that could overcome multidrug resistance in tuberculosis

Using a high-throughput screening assay, EPFL scientists have discovered two small molecules that could overcome the multidrug resistance of the bacterium that causes tuberculosis.

9 Oct 2014

Viewpoints: Walmart's cuts in insurance grow from health law; online marketplace still lacks transparency

Wal-Mart gave lawmakers a concise lesson in economics Tuesday when it disclosed that it would no longer offer health insurance to yet more of its part-time employees. ... I'll just argue that what we're seeing is the entirely predictable result of the employer mandate in the 2010 Patient Protection and Affordable Care Act -- a mandate, by the way, that Wal-Mart lobbied for. The company was offering health benefits for most employees at the time, and may simply have been trying to force its competitors to do the same (Jon Healey, 10/7).

9 Oct 2014

Researchers use computer based predictions to combat AIDS

The battle against AIDS cannot be won in the laboratory alone. To fight the potentially deadly virus that 34 million people are suffering from we need help from computers.

8 Oct 2014

Health Canada approves Lucentis (ranibizumab) for myopic CNV

Novartis Pharmaceuticals Canada Inc. announced today that Lucentis (ranibizumab), the treatment for several major causes of vision loss, has been approved by Health Canada for the treatment of visual impairment due to choroidal neovascularization (CNV) secondary to pathologic myopia (myopic CNV).

8 Oct 2014

Boehringer Ingelheim announces availability of Striverdi Respimat Inhalation Spray 5 mcg in the U.S.

Boehringer Ingelheim today announced that Striverdi Respimat (olodaterol) Inhalation Spray 5 mcg is now available by prescription in pharmacies across the United States.

8 Oct 2014

Pharmaceuticals News and Research

Gedeon Richter implements MediaSoft's innovative CRM solutions to improve customer-oriented services

Pharmaceutical industry withdraws from the antibiotic space

OBN, ABPI sign MoU to build a better public profile

Drugmakers sue to stop expansion of drug discount program

Maker of experimental Ebola drug scales up

Preoperative IV ibuprofen improves quality of recovery after laparoscopic cholecystectomy surgery

Isis Pharmaceuticals provides update on Phase 2 clinical studies of ISIS-SMN Rx in children with SMA

European experts publish common vision of priorities for marine research

GE Healthcare-Glaxo Smith Kline deal to create force in cancer testing

VAL-083 drug compound shows promise against non-small cell lung cancer

HemoShear completes first-phase development of novel cancer drug discovery platform

Isis Pharmaceuticals secures $18 million from GSK to advance ISIS-TTR Rx Phase 2/3 study

CytRx begins Phase 1b trial of aldoxorubicin plus gemcitabine in patients with metastatic solid tumors

Endo International enters into definitive agreement to acquire Auxilium Pharmaceuticals

Impax executes definitive agreement to acquire Tower Holdings, Lineage Therapeutics

EPFL scientists discover two molecules that could overcome multidrug resistance in tuberculosis

Viewpoints: Walmart's cuts in insurance grow from health law; online marketplace still lacks transparency

Researchers use computer based predictions to combat AIDS

Health Canada approves Lucentis (ranibizumab) for myopic CNV

Boehringer Ingelheim announces availability of Striverdi Respimat Inhalation Spray 5 mcg in the U.S.

Event guide: 3rd EHS for Biopharma Summit eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Managing vibration in IVF laboratories

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence